Jefferies analyst Jeffrey Holford raised his price target on Buy-rated Pfizer (NYSE: PFE) to $45.00 (from $42.00) and added the stock to the Jefferies "Franchise Picks" list. Holford commented, "We expect PFE shares to significantly …
Pharma titan Pfizer (NYSE:PFE) announced second-quarter earnings on Tuesday, but the drugmaker's performance was clearly a secondary issue for analysts and investors alike. Despite beating consensus on adjusted earnings per share …
Dr. David Hung, who guided cancer drug developer Medivation Inc. through a bidding sweepstakes that culminated in a $14 billion cash offer by Pfizer Inc., could reap change-of-control payouts worth upwards of $150 million. Hung, who founded …
U.K.-based pharmaceutical company AstraZeneca (AZN) announced on Monday that it has rejected American pharmaceutical firm Pfizer’s (PFE) offer over the weekend to buy the company for 55GBP per share. Pfizer offered $120 …
With the start of a new trading month upon us, it is time, once again, to lay out a plan for my potential stock picks. As many of you do the same, I’m sure you have come to the realization that this current market continues to defy a lot of …
Today's Daily Dose brings you news about Clearside Biomedical's phase II TYBEE trial; Ocular's huge disappointment for second time on its product candidate DEXTENZA; Oramed's upcoming end-of-phase II meeting with the FDA for oral …
Benjamin Graham taught that Intelligent Investors must do a thorough fundamental analysis of investment opportunities to determine their intrinsic value and inherent risk. This is best done by utilizing a systematic approach to analysis that …
FX Empire - the company, employees, subsidiaries and associates, are not liable nor shall they be held liable jointly or severally for any loss or damage as link result of reliance on the information provided on this website. The data …